Global Parkinson's Disease Treatment Market Insights Forecasts to 2033

• The Global Parkinson's Disease Treatment Market Size was Valued at USD 4.91 Billion in 2023
• The Market Size is Growing at a CAGR of 6.41% from 2023 to 2033
• The Worldwide Parkinson's Disease Treatment Market Size is Expected to Reach USD 9.14 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

 

Get more details on this report -

Request Free Sample PDF

 

The Parkinson's Disease Treatment Market Size is Anticipated to Exceed USD 9.14 Billion by 2033, Growing at a CAGR of 6.41% from 2023 to 2033.

 

Market Overview

Parkinson's disease is a neurological condition that primarily results in unintentional or uncontrollable movements, including stiffness, shaking, and trouble balancing and coordinating. Because the precise cause of nerve cell degeneration is unknown, genetics and exposure to environmental risk factors are thought to be likely causes. The symptoms start mildly and get worse with time. As the illness progresses, people may experience difficulty in moving and communicating. The patient may also have memory loss, sleep problems, depression, and behavioral changes. Parkinson's disease can virtually always strike anyone, but some research suggests that men are more susceptible than women. One of the most common symptoms of Parkinson's disease is the impairment and death of nerve cells in the basal ganglia. Parkinson's disease has a significant effect on norepinephrine, the main chemical messenger of the sympathetic nervous system that regulates blood pressure and heart rate, among other vital processes. Around the world, the prevalence of Parkinson's disease is rising due to environmental causes, poor lifestyle choices, and an aging population. Additional factors driving market growth are the availability of effective treatments for Parkinson's disease and growing patient and physician awareness of the ailment. Market participants are engaged in the development of novel medications that could decrease the symptoms of Parkinson's disease, even though there is no known cure for the illness.

 

Report Coverage

This research report categorizes the market for the Parkinson's disease treatment market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Parkinson's disease treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Parkinson's disease treatment market.

 

Driving Factors

The rapid aging of the population, increased public awareness of Parkinson's disease, and the anticipated release of novel treatments are propelling the market for Parkinson's disease treatments. The growing accessibility and availability of various supporting therapies and pharmaceuticals for the treatment of Parkinson's disease will drive market growth. Moreover, the number of patients visiting hospitals to receive a diagnosis of Parkinson's disease is being driven by the expansion of diagnostic laboratory availability.

 

Restraining Factors

Parkinson's disease medications are typically safe there are a few potential adverse effects though. Important Parkinson's disease treatment processes involve the use of these medications. For their items to be sold in each region, producers must obtain product approvals from various individuals.

 

Market Segmentation

The Parkinson’s disease treatment market share is classified into drug class, route of administration and distribution channel.

 

• The carbidopa-levodopa segment dominated the market with the largest revenue share through the forecast period.

Based on the drug class, the Parkinson’s disease treatment market is categorized into carbidopa-levodopa, dopamine agonists, monoamine oxidase type B (MAO-B) inhibitor, catechol-o-methyltransferase (COMT) inhibitors, and others. Among these, the carbidopa-levodopa segment dominated the market with the largest revenue share through the forecast period. The combination of carbidopa-levodopa is one of the best ways to treat Parkinson's disease. It is frequently utilized as a second line of treatment since it is the most effective.

 

• The oral segment accounted for the market with the largest market share through the forecast period.

Based on the route of administration, the Parkinson’s disease treatment market is categorized into oral, subcutaneous, transdermal, and others. Among these, the oral segment accounted for the market with the largest market share through the forecast period. As medications or active substances are administered orally, they pass via the digestive tract and into the bloodstream. The patient swallows the medication, often administered as a pill, capsule, or liquid.

 

• The hospital pharmacy segment is anticipated to grow at the fastest CAGR growth through the forecast period.

Based on the distribution channel, the Parkinson’s disease treatment market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, the hospital pharmacy segment is anticipated to grow at the fastest CAGR growth through the forecast period. As the main distribution route for both branded and generic anti-Parkinson's medications is through hospital pharmacies. The reasons expected to propel the segment's expansion include the increase in the number of patients with Parkinson's disease and the convenience with which different types of dosage forms may be obtained at hospital pharmacies.

 

Regional Segment Analysis of the Parkinson’s Disease Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the Parkinson’s disease treatment market over the predicted timeframe.

Get more details on this report -

Request Free Sample PDF

North America is projected to hold the largest share of the Parkinson’s disease treatment market over the forecast period. Because of the aging population, there is a larger demand for therapy as the number of people with this illness receiving diagnoses rises. North America boasts a highly developed healthcare infrastructure together with state-of-the-art medical facilities and technology. Because it makes it possible for an early diagnosis, comprehensive therapy, and better control of Parkinson's disease, this raises the demand for pharmaceuticals. The area is home to numerous respected pharmaceutical companies and research centers that invest much in the study and treatment of Parkinson’s disease. As a result, the market for Parkinson's disease therapies is constantly receiving new and innovative treatments.

 

Asia Pacific is expected to grow at the fastest CAGR growth of the Parkinson’s disease treatment market during the forecast period. The regional market is expected to rise as a result of an increase in government spending and the number of patients. The expansion of the regional market is also anticipated to be aided by favorable government policies and a rise in research and development efforts.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Parkinson’s disease Treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Abbott Laboratories
• General Electric Company
• Abbvie
• Merck & Co.
• Pfizer
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories
• Sun Pharma
• Novartis AG
• Olatec Therapeutics
• Biotech Ltd
• Amneal Pharmaceuticals LLC
• Zydus Cadila
• Hallamshire Physiotherapy Ltd
• Wockhardt Ltd.
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments

• In January 2024, The European launch of Produodopa was announced by AbbVie. When advanced Parkinson's disease is present, produodopa can help with hyperkinesia or dyskinesia, significant motor fluctuations, and other symptoms.

 

• In August 2023, Acorda Therapeutics, Inc. declared the opening of a new website and marketing campaign for INBRIJA (levodopa inhalation powder). The "For the Fighters" campaign is based on firsthand comments from Parkinson's disease patients (PwPs).

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Parkinson’s disease treatment market based on the below-mentioned segments: 

 

Global Parkinson’s Disease Treatment Market, By Drug Class

• Carbidopa-levodopa
• Dopamine Agonists
• Monoamine Oxidase Type B (MAO-B) Inhibitor
• Catechol-O-Methyltransferase (COMT) Inhibitor
• Others

 

Global Parkinson’s Disease Treatment Market, By Route of Administration

• Oral
• Subcutaneous
• Transdermal
• Others

 

Global Parkinson’s Disease Treatment Market, By Distribution Channels

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

 

Global Parkinson’s Disease Treatment Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa